Skip to main content
. Author manuscript; available in PMC: 2014 Mar 5.
Published in final edited form as: J Immunol. 2009 Apr 1;182(7):3985–3994. doi: 10.4049/jimmunol.0803053

Fig. 1. Anti-CD25 antibody administration significantly modulates the outcome of acute T. gondii infection.

Fig. 1

Groups of 5 B6 males were given 1 mg control mAb (HRPN) or anti-CD25 (PC61) 5 or 7 days before oral infection with 10 ME49 cysts. (A) Changes in body weight were monitored and are presented as percentage change relative to starting weight. Symbols show mean ± std. dev. *, significant differences (p<0.05). (B) Compiled survival data from 3 experiments comparing anti-CD25-treated with control T. gondii-infected B6 male mice. Survivals differed significantly (p<0.01) by log-rank test. (C) Brain cysts of 3 anti-CD25-treated B6 male mice, and 5 controls 28 days after mice were sham-infected or infected with 10 ME49 cysts. Horizontal lines denote medians. (D) On day 8 post-infection livers and ileums were removed and stained with H & E for histological examination of tissue pathology with arrows marking areas of inflammation or necrosis (also marked by *). (E, F) On day 8 post-infection (E) livers and (F) ileums were removed for real-time PCR (taqman) quantification of tissue parasite burdens. The results shown are the mean ± std. dev. of the group (n = 5) and are representative of 2 independent experiments. ** (p<0.01).